Virginia Retirement Systems ET AL Invests $1.07 Million in Myriad Genetics, Inc. (MYGN)

Share on StockTwits

Virginia Retirement Systems ET AL bought a new position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in the second quarter, Holdings Channel reports. The institutional investor bought 28,600 shares of the company’s stock, valued at approximately $1,069,000.

Several other hedge funds also recently added to or reduced their stakes in the company. Piedmont Investment Advisors LLC increased its stake in shares of Myriad Genetics by 1.9% during the second quarter. Piedmont Investment Advisors LLC now owns 70,179 shares of the company’s stock worth $2,623,000 after purchasing an additional 1,285 shares in the last quarter. Amalgamated Bank grew its stake in Myriad Genetics by 14.0% during the 2nd quarter. Amalgamated Bank now owns 10,611 shares of the company’s stock valued at $397,000 after acquiring an additional 1,302 shares in the last quarter. CWM LLC grew its stake in Myriad Genetics by 0.6% during the 2nd quarter. CWM LLC now owns 282,289 shares of the company’s stock valued at $10,549,000 after acquiring an additional 1,650 shares in the last quarter. Royal Bank of Canada grew its stake in Myriad Genetics by 59.5% during the 1st quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock valued at $136,000 after acquiring an additional 1,715 shares in the last quarter. Finally, Great West Life Assurance Co. Can grew its stake in Myriad Genetics by 2.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 92,760 shares of the company’s stock valued at $2,740,000 after acquiring an additional 1,858 shares in the last quarter.

NASDAQ:MYGN opened at $41.67 on Monday. The company has a current ratio of 3.52, a quick ratio of 3.16 and a debt-to-equity ratio of 0.07. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of 39.69, a PEG ratio of 2.87 and a beta of 0.49. Myriad Genetics, Inc. has a 1-year low of $27.23 and a 1-year high of $44.87.

Several analysts recently issued reports on MYGN shares. TheStreet raised shares of Myriad Genetics from a “c+” rating to a “b” rating in a research note on Monday, June 4th. ValuEngine cut shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 21st. BTIG Research set a $42.00 price objective on shares of Myriad Genetics and gave the company a “buy” rating in a research note on Tuesday, May 8th. Morgan Stanley upped their price objective on shares of Myriad Genetics from $33.00 to $35.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 9th. Finally, Zacks Investment Research cut shares of Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 18th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $36.40.

In other Myriad Genetics news, Director Dennis Langer sold 49,631 shares of the business’s stock in a transaction dated Tuesday, June 5th. The shares were sold at an average price of $39.30, for a total value of $1,950,498.30. Following the transaction, the director now directly owns 69,743 shares in the company, valued at approximately $2,740,899.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Richard M. Marsh sold 70,672 shares of the business’s stock in a transaction dated Wednesday, July 11th. The shares were sold at an average price of $42.88, for a total transaction of $3,030,415.36. Following the completion of the transaction, the vice president now owns 154,869 shares in the company, valued at $6,640,782.72. The disclosure for this sale can be found here. Insiders sold a total of 496,811 shares of company stock worth $19,897,716 over the last quarter. 6.70% of the stock is currently owned by company insiders.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Recommended Story: Trading Strategy Examples and Plans

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply